Chemistry:Mitozolomide
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C7H7ClN6O2 |
| Molar mass | 242.62 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]
References
- ↑ "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide". Cancer Gene Ther 7 (2): 233–9. February 2000. doi:10.1038/sj.cgt.7700120. PMID 10770631. http://www.nature.com/cgt/journal/v7/n2/pdf/7700120a.pdf.
- ↑ "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer 65 (2): 287–91. February 1992. doi:10.1038/bjc.1992.57. PMID 1739631.
 |  |
